The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
In Vivo Activity Against HIV and Favorable Toxicity Profile of 2′,3′-Dideoxyinosine
Abstract
The purine analog 2′,3′-dideoxyinosine (ddI), which has anti-retroviral activity in vitro was administered for up to 42 weeks to 26 patients with acquired immunodeficiency syndrome (AIDS) or severe AIDS-related complex (ARC). Ten of these individuals were AZT-intolerant. Eight dose regimens were studied. The drug was orally bioavailable and penetrated into the cerebrospinal fluid (CSF). Comparatively little evidence of an effect against human immunodeficiency virus (HIV) was seen at the lowest four doses. However, patients in the four highest dose groups (ddI at 1.6 milligrams per kilogram intravenously and then ≥ 3.2 milligrams per kilogram orally at least every 12 hours or higher) had increases in their circulating CD4 + T cells (P < 0.0005), increased CD4/CD8 T cell ratios (P < 0.01), and, where evaluable, more than an 80% decrease in serum HIV p24 antigen (P < 0.05). The patients also had evidence of improved immunologic function, had reduced viremic symptomatology, and gained a mean of 1.6 kilogram with these comparatively infrequent dosing schedules (every 8 or 12 hours). The most notable adverse effects directly attributable to ddI administration at the doses used in this study included increases in serum uric acid (due to hypoxanthine release) and mild headaches and insomnia. These results suggest that serious short-term toxicity at therapeutic doses is not an inherent feature in the profile of agents with clinical anti-HIV activity. Further controlled studies to define the safety and efficacy of this agent may be worth considering.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Fischl, M. A., Richman, D. D., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Schooley, R. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170401 · Cited by 2,995
Jonjić, S., Mutter, W., Weiland, F., Reddehase, M. J., & Koszinowski, U. H. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.4.1199 · Cited by 2,105
HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy
Larder, B. A., Darby, G., & Richman, D. D. (1989) · Science · doi:10.1126/science.2467383 · Cited by 1,559
The Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Richman, D. D., Fischl, M. A., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Hirsch, M. S., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170402 · Cited by 1,199
Mitsuya, H., & Broder, S. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.6.1911 · Cited by 1,039
Self-citationYarchoan, R., Weinhold, K., Lyerly, H. K., Gelmann, E., Blum, R., Shearer, G., Mitsuya, H., Collins, J., Myers, C., Klecker, R., et al. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92808-4 · Cited by 802
Self-citationYARCHOAN, R. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90283-8 · Cited by 512
Self-citationGoudsmit, J., Paul, D., Lange, J. A., Speelman, H., Van Der Noordaa, J., Van Der Helm, H., De Wolf, F., Epstein, L., Krone, W. A., Wolters, E., et al. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92485-2 · Cited by 512
CD4 Counts as Predictors of Opportunistic Pneumonias in Human Immunodeficiency Virus (HIV) Infection
Masur, H., Ognibene, F. P., Yarchoan, R., Shelhamer, J. H., Baird, B. F., Travis, W., Suffredini, A. F., Deyton, L., Kovacs, J. A., Falloon, J., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-3-223 · Cited by 500
Self-citationStrategies for antiviral therapy in AIDS
Mitsuya, H., & Broder, S. (1987) · Nature · doi:10.1038/325773a0 · Cited by 487
Self-citationPizzo, P. A., Eddy, J., Falloon, J., Balis, F. M., Murphy, R. F., Moss, H., Wolters, P., Brouwers, P., Jarosinski, P., Rubin, M., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198810063191401 · Cited by 449
Self-citationBrahams, D. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90167-8 · Cited by 440
Schmitt, F. A., Bigley, J. W., McKinnis, R., Logue, P. E., Evans, R. W., Drucker, J. L., & The AZT Collaborative Working Group* (1988) · New England Journal of Medicine · doi:10.1056/nejm198812153192404 · Cited by 396
Yarchoan, R., Brouwers, P., Robert Spitzer, A., Grafman, J., Safai, B., Perno, C., Larson, S., Berg, G., Fischl, M., Wichman, A., et al. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91968-4 · Cited by 352
Self-citationPerno, C. F., Yarchoan, R., Cooney, D. A., Hartman, N. R., Webb, D. S., Hao, Z., Mitsuya, H., Johns, D. G., & Broder, S. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.3.933 · Cited by 285
Self-citationANTI-RETROVIRAL EFFECTS OF INTERFERON-α IN AIDS-ASSOCIATED KAPOSI'S SARCOMA
Clifford Lane, H., Feinberg, J., Davey, V., Deyton, L., Baseler, M., Manischewitz, J., Masur, H., Kovacs, J., Herpin, B., Walker, R., et al. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90811-2 · Cited by 261
SERUM-SICKNESS-LIKE SYNDROME WITH MEMBRANOUS GLOMERULOPATHY IN PATIENT ON CAPTOPRIL
Hoorntje, S., Weening, J., Kallenberg, C. M., Prins, E. L., & Donker, A. M. (1979) · The Lancet · doi:10.1016/s0140-6736(79)92303-1 · Cited by 225
SEPTICÆMIA DUE TO PORCINE STREPTOCOCCI
Kloppenburg, M., Mulder, N. H., & Houwerzijl, J. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92719-1 · Cited by 212
Merigan, T. C., Skowron, G., Bozzette, S. A., Richman, D., Uttamchandani, R., Fischl, M., Schooley, R., Hirsch, M., Soo, W., Pettinelli, C., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-3-189 · Cited by 212
Mitsuya, H., Jarrett, R. F., Matsukura, M., Di Marzo Veronese, F., DeVico, A. L., Sarngadharan, M. G., Johns, D. G., Reitz, M. S., & Broder, S. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.7.2033 · Cited by 203
Self-citationEFFECTS OF ZIDOVUDINE IN 365 CONSECUTIVE PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX
Dournon, E., Rozenbaum, W., Michon, C., Perronne, C., De Truchis, P., Bouvet, E., Levacher, M., Matheron, S., Gharakhanian, S., Girard, P. M., et al. (1988) · The Lancet · doi:10.1016/s0140-6736(88)92903-0 · Cited by 175
SEVERELY DISTURBED ADOLESCENTS
(1970) · The Lancet · doi:10.1016/s0140-6736(70)90823-8 · Cited by 171
Survival Experience Among Patients With AIDS Receiving Zidovudine
Creagh-Kirk, T. (1988) · JAMA · doi:10.1001/jama.1988.03410200065027 · Cited by 171
Konotey-Ahulu, F. I. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90713-1 · Cited by 10
Cited by
Molecular Targets for AIDS Therapy
Mitsuya, H., Yarchoan, R., & Broder, S. (1990) · Science · doi:10.1126/science.1699273 · Cited by 732
Self-citationResistance to ddI and Sensitivity to AZT Induced by a Mutation in HIV-1 Reverse Transcriptase
St. Clair, M. H., Martin, J. L., Tudor-Williams, G., Bach, M. C., Vavro, C. L., King, D. M., Kellam, P., Kemp, S. D., & Larder, B. A. (1991) · Science · doi:10.1126/science.1716788 · Cited by 679
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
Broder, S. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.10.002 · Cited by 520
Self-citationKovacs, J. A., Baseler, M., Dewar, R. J., Vogel, S., Davey, R. T., Falloon, J., Polis, M. A., Walker, R. E., Stevens, R., Salzman, N. P., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503023320904 · Cited by 425
RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase.
Tuerk, C., MacDougal, S., & Gold, L. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.15.6988 · Cited by 415
Metadata
- Authors
- Yarchoan, R., Mitsuya, H., Thomas, R. V., Pluda, J. M., Hartman, N. R., Perno, C.-F., Marczyk, K. S., Allain, J.-P., Johns, D. G., & Broder, S.
- Venue
- Science
- Published
- 1989-07-28
- Volume
- 245
- Issue
- 4916
- Pages
- 412-415
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2034209707
- Cited by
- 427
- References
- 24
- FWCI
- 53.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.